Monthly Prescribing Reference

NEAT Trial: No Significant Improvement With eDSP in Ataxia-Telangiectasia

In the phase 3 NEAT trial, eDSP was well tolerated but did not significantly reduce neurological symptoms in patients with ataxia-telangiectasia. Topline data were announced from a phase 3 trial ...
Nasdaq

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...
Hosted on MSN

Quince Therapeutics publishes summary of early-stage clinical studies of eDSP

Quince Therapeutics (QNCX) “announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate encapsulated in a patient’s own red ...
Seeking Alpha

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of ...
Morningstar

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication ...